Fig. 6. In vivo antitumor efficacy of liposomal nanomedicines in an A549 xenograft mouse model. (a) The overall schedule of subcutaneous A549 mouse model establishment and drug administration. Mice (n = 7) bearing A549 tumors were intravenously treated with saline, CPT-11 or Chol-SN38@LP (15 mg kg⁻¹ SN38 equiv.) every three days three times. The tumor size and body weight were recorded from day 0 to the end of observation at day 30. (b) The tumor growth curves of mice in each group. Photographs of the excised tumors in each group at the end of the experiment (c) and the tumor weight of excised tumors (d). (e) Body weight variation throughout treatment. Representative H&E staining, immunofluorescence staining (TUNEL) and immunohistological staining (Ki-67 and γ-H2A.X) of tumors excised at day 9 (f). The quantification of positive area ratio of TUNEL (g), Ki-67 (h) and γ-H2A.X (i).